Core Viewpoint - The construction of medical alliances is a crucial measure for deepening healthcare reform, optimizing resource allocation, and enhancing grassroots medical service capabilities. While progress has been made in Beijing's medical alliance construction, there are still shortcomings that need to be addressed [1]. Group 1: Drug Supply Issues - There is a contradiction in the supply of various drugs at grassroots hospitals, which affects patients' willingness to seek care at these facilities. The limited variety of drugs available due to storage conditions and funding constraints impacts patient choice [1]. - The lack of a unified drug directory among different medical institutions within the medical alliance restricts the collaborative diagnostic and treatment capabilities of the alliance [1]. Group 2: Special Drug Accessibility - The process for patients with chronic diseases to apply for necessary drugs at community hospitals is complex and lacks clear timelines for procurement and delivery. A suggestion is made to adopt a "library inter-borrowing" model to facilitate centralized daily distribution of drugs from large hospitals [2]. - There is a significant shortage of pediatric medications in grassroots hospitals, particularly for common childhood diseases, which affects the ability to alleviate the pressure on large hospitals' pediatric departments [2]. Group 3: Innovation Drug Accessibility - The acceleration of innovative drug development and their inclusion in the national medical insurance directory face challenges in reaching grassroots hospitals. A proposal is made to establish a fast-track approval process for innovative drugs within the medical alliance [3]. - It is recommended to optimize the medical insurance reimbursement policy for innovative drugs included in the shared directory of the medical alliance, potentially increasing the reimbursement ratio for grassroots facilities to reduce patient financial burdens [3].